News - Ipsen, Syntaxin

Filter

Current filters:

IpsenSyntaxin

Popular Filters

Syntaxin and Ipsen in up to $99 million collaboration on novel botulinum-toxin therapeutics

21-10-2011

French drugmaker Ipsen (Euronext: IPN) has entered into a global strategic collaboration with privately-held…

BiotechnologyIpsenLicensingPharmaceuticalResearchSyntaxin

Back to top